SS Innovations International, Inc. (NASDAQ: SSII) announced significant growth in the utilization and global reach of its SSi Mantra surgical robotic system. As of September 8, 2026, cumulative procedures performed using the system reached 14,103, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems grew 42% to 238 units, up from 168 at year-end 2025. These figures underscore the company's expanding footprint in the global surgical robotics market.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's progress in making robotic surgery accessible across diverse geographies.
SS Innovations also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a telesurgery spanning more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system's efficiency and high-volume capacity. Such achievements are critical as they demonstrate the platform's reliability and potential to address surgical needs in both developed and emerging markets.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are pivotal for the company's expansion into two of the largest healthcare markets, potentially unlocking significant new revenue streams and further validating the technology's safety and efficacy.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company's product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. To view the full report, visit https://ibn.fm/DJILj.
